Join Urology Times and Contemporary Pediatrics for a discussion about controversies over circumcision and its implications.
A new national survey shows severe physician shortages among certain pediatric specialties, and pediatric urologists top the list of those registering long wait times for pediatric surgical care.
Stone disease and minimally invasive treatment approaches are once again leading issues in the pediatric urology section of the 2012 AUA annual meeting.
Use of dextranomer/hyaluronic acid copolymer (Deflux) for vesicoureteral reflux rising; long-term results vary
Use of Dx/HA (Deflux) for the treatment of vesicoureteral reflux (VUR) in children increased rapidly after it gained FDA approval. Despite high rates of utilization and positive early findings, more recent reports are raising questions about long-term outcomes and prompting further research.
Although stone disease in pediatric patients is on the rise and minimally invasive techniques to deal with it are increasing, there is a lack of evidence-based standards to care for these patients.
Hypocitraturia is the leading metabolic risk factor in children with stone disease, and the majority of a study's cohort had an identifiable metabolic cause for their urolithiasis.
New data showing an increasing incidence of pediatric stone disease is stimulating more research to further describe and understand this troubling phenomenon.
Radiologically proven VUR was present in 11 mothers and seven fathers as well as in 36 second-degree relatives (aunts, uncles, grandparents) and 73 third-degree relatives (65 first cousins and eight great-aunts, -uncles or -grandparents) of 259 VUR patients in an Irish study.
Downgrading of high-grade vesicoureteral reflux (VUR) after endoscopic treatment performed because of breakthrough urinary tract infections results in cessation of febrile UTIs and, often, spontaneous VUR resolution as well.
Urologists' reports of stones in pediatric patients varies by region.